The biological and medical importance of the endogenously generated  gaseous transmitter nitric oxide was recognized by the 1998 Nobel Prize  for Medicine/Physiology. It is now clear that several “gasotransmitters” 
 exist and this class of mediators also includes carbon monoxide and  hydrogen sulfide. Translational research on gasotransmitters has  exploded over the past years.  Drugs that alter the production/levels of  the gaseous mediators themselves or modulate the signaling pathways  they act by are already in use in clinical use, and still more are being  evaluated in preclinical models and clinical trials.
 

The biological and medical importance of the endogenously generated gaseous transmitter nitric oxide was recognized by the 1998 Nobel Prize for Medicine/Physiology. It is now clear that several “gasotransmitters” exist and this class of mediators also includes carbon monoxide and hydrogen sulfide. Translational research on gasotransmitters has exploded over the past years. Drugs that alter the production/levels of the gaseous mediators themselves or modulate the signaling pathways they act by are already in use in clinical use, and still more are being evaluated in preclinical models and clinical trials.

The biological and medical importance of the endogenously generated gaseous transmitter nitric oxide was recognized by the 1998 Nobel Prize for Medicine/Physiology. It is now clear that several “gasotransmitters” exist and this class of mediators also includes carbon monoxide and hydrogen sulfide. Translational research on gasotransmitters has exploded over the past years. Drugs that alter the production/levels of the gaseous mediators themselves or modulate the signaling pathways they act by are already in use in clinical use, and still more are being evaluated in preclinical models and clinical trials.

The biological and medical importance of the endogenously generated gaseous transmitter nitric oxide was recognized by the 1998 Nobel Prize for Medicine/Physiology. It is now clear that several “gasotransmitters” exist and this class of mediators also includes carbon monoxide and hydrogen sulfide. Translational research on gasotransmitters has exploded over the past years. Drugs that alter the production/levels of the gaseous mediators themselves or modulate the signaling pathways they act by are already in use in clinical use, and still more are being evaluated in preclinical models and clinical trials.

     

Home Hot Papers of the Month Hot Papers of September 2015-January 2016

Mon,01May2017

Hot Papers of September 2015-January 2016

Hot Papers of the Month- June/July

ESF

COST

POLICY STATEMENT: Biomedicine and Molecular Biosciences Action BM1005 is funded by COST, through its implementing agent the European Science Foundation.